{"Q": 1, "answer": "no", "rationale": "The segment does not contain an intensifier or comparative directly modifying a risk-adjective.", "method": "llm_batch", "batch_id": "batch_1_20904", "batch_size": 200, "batch_pos": 82, "statement_text": "U.S. officials said on a press call that late-stage testing would begin in 2025, pending results expected in the coming weeks of Moderna's phase 1 trial.", "article_id": 1745}
{"Q": 2, "answer": "no", "rationale": "The segment does not contain any high-potency verbs, potent metaphors, critical alert phrases, superlatives + harm nouns, or intensifiers + harm nouns.", "method": "llm_batch", "batch_id": "batch_2_12192", "batch_size": 200, "batch_pos": 51, "statement_text": "U.S. officials said on a press call that late-stage testing would begin in 2025, pending results expected in the coming weeks of Moderna's phase 1 trial.", "article_id": 1745}
{"Q": 3, "answer": "no", "rationale": "The segment does not contain a moderate verb from the specified list paired with explicit scale or impact information.", "method": "llm_batch", "batch_id": "batch_3_19772", "batch_size": 200, "batch_pos": 197, "statement_text": "U.S. officials said on a press call that late-stage testing would begin in 2025, pending results expected in the coming weeks of Moderna's phase 1 trial.", "article_id": 1745}
{"Q": 4, "answer": "no", "rationale": "The segment does not contain a loaded rhetorical question.", "method": "llm_batch", "batch_id": "batch_4_18480", "batch_size": 200, "batch_pos": 186, "statement_text": "U.S. officials said on a press call that late-stage testing would begin in 2025, pending results expected in the coming weeks of Moderna's phase 1 trial.", "article_id": 1745}
{"Q": 5, "answer": "no", "rationale": "Reports a plan/timeline; no explicit calming cues.", "method": "llm_batch", "batch_id": "batch_5_14692", "batch_size": 200, "batch_pos": 182, "statement_text": "U.S. officials said on a press call that late-stage testing would begin in 2025, pending results expected in the coming weeks of Moderna's phase 1 trial.", "article_id": 1745}
{"Q": 6, "answer": "no", "rationale": "The segment does not contain a minimiser word combined with a scale contrast.", "method": "llm_batch", "batch_id": "batch_6_7996", "batch_size": 200, "batch_pos": 126, "statement_text": "U.S. officials said on a press call that late-stage testing would begin in 2025, pending results expected in the coming weeks of Moderna's phase 1 trial.", "article_id": 1745}
{"Q": 7, "answer": "no", "rationale": "Segment does not contain a bare negation.", "method": "llm_batch", "batch_id": "batch_7_20124", "batch_size": 200, "batch_pos": 103, "statement_text": "U.S. officials said on a press call that late-stage testing would begin in 2025, pending results expected in the coming weeks of Moderna's phase 1 trial.", "article_id": 1745}
{"Q": 8, "answer": "yes", "rationale": "The segment describes future testing/development timeline: 'late-stage testing would begin'.", "method": "llm_batch", "batch_id": "batch_8_15292", "batch_size": 200, "batch_pos": 72, "statement_text": "U.S. officials said on a press call that late-stage testing would begin in 2025, pending results expected in the coming weeks of Moderna's phase 1 trial.", "article_id": 1745}
